How to select older patients with acute myeloid leukemia fit
for intensive treatment?

J 2021

How to select older patients with acute myeloid leukemia fit for intensive treatment?

ŠUSTKOVÁ, Zuzana, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ and Jiří MAYER

Basic information

Original name

How to select older patients with acute myeloid leukemia fit for intensive treatment?

Authors

ŠUSTKOVÁ, Zuzana (203 Czech Republic, guarantor), Lukáš SEMERÁD (203 Czech Republic), Barbora WEINBERGEROVÁ (203 Czech Republic) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2021, 0278-0232

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.850

RIV identification code

RIV/00216224:14110/21:00120701

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/hon.2798

UT WoS

000566365200001

Keywords in English

AML; elderly; geriatric assessment; negative prognostic factors; older patients

Abstract

V originále

Outcomes of the treatment of older patients with acute myeloid leukemia (AML) are unsatisfactory due to a higher incidence of negative patient- and disease-related risk factors connected with aging. Prediction of poor tolerance to aggressive treatment and low response to standard intensive chemotherapy are the main root causes why the treatment decision is challenging. For a long time, negative prognostic factors for treatment outcomes, overall survival, and early death such as the age itself, low-performance status, high-comorbidity burden, adverse cytogenetics, and secondary AML have been known, and they are routinely taken into account during therapeutic balance. In consideration of the risk factors and specific laboratory results, prognostic models have been created. Despite the abovementioned facts, the survival of older patients with AML remains very poor, that holds true even for the intensive therapy. For that reason, there is an increased effort to find a better approach how to select patients who would benefit from intensive treatment without decreasing their quality of life through severe complications with risk of high treatment-related mortality. Based on the results of clinical studies, the geriatric assessment could be the missing step which would help select older patients who are really fit for intensive treatment and who will benefit from it the most. This review focuses on the risk factors that should be taken under advisement when the decision about the treatment is made. With reference to the published information, we propose an algorithm how to identify fit, vulnerable, and frail patients.

Citovat

ŠUSTKOVÁ, Zuzana, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ and Jiří MAYER. How to select older patients with acute myeloid leukemia fit for intensive treatment? Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2021, vol. 39, No 2, p. 151-161. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2798.

@article{1679122,
   author = {Šustková, Zuzana and Semerád, Lukáš and Weinbergerová, Barbora and Mayer, Jiří},
   article_location = {MALDEN, USA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/hon.2798},
   keywords = {AML; elderly; geriatric assessment; negative prognostic factors; older patients},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {How to select older patients with acute myeloid leukemia fit for intensive treatment?},
   url = {https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2798},
   volume = {39},
   year = {2021}
}

TY  - JOUR
ID  - 1679122
AU  - Šustková, Zuzana - Semerád, Lukáš - Weinbergerová, Barbora - Mayer, Jiří
PY  - 2021
TI  - How to select older patients with acute myeloid leukemia fit for intensive treatment?
JF  - Hematological Oncology
VL  - 39
IS  - 2
SP  - 151-161
EP  - 151-161
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - AML
KW  - elderly
KW  - geriatric assessment
KW  - negative prognostic factors
KW  - older patients
UR  - https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2798
L2  - https://onlinelibrary.wiley.com/doi/full/10.1002/hon.2798
N2  - Outcomes of the treatment of older patients with acute myeloid leukemia (AML) are unsatisfactory due to a higher incidence of negative patient- and disease-related risk factors connected with aging. Prediction of poor tolerance to aggressive treatment and low response to standard intensive chemotherapy are the main root causes why the treatment decision is challenging. For a long time, negative prognostic factors for treatment outcomes, overall survival, and early death such as the age itself, low-performance status, high-comorbidity burden, adverse cytogenetics, and secondary AML have been known, and they are routinely taken into account during therapeutic balance. In consideration of the risk factors and specific laboratory results, prognostic models have been created. Despite the abovementioned facts, the survival of older patients with AML remains very poor, that holds true even for the intensive therapy. For that reason, there is an increased effort to find a better approach how to select patients who would benefit from intensive treatment without decreasing their quality of life through severe complications with risk of high treatment-related mortality. Based on the results of clinical studies, the geriatric assessment could be the missing step which would help select older patients who are really fit for intensive treatment and who will benefit from it the most. This review focuses on the risk factors that should be taken under advisement when the decision about the treatment is made. With reference to the published information, we propose an algorithm how to identify fit, vulnerable, and frail patients.
ER  -

ŠUSTKOVÁ, Zuzana, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ and Jiří MAYER. How to select older patients with acute myeloid leukemia fit for intensive treatment? \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2021, vol.~39, No~2, p.~151-161. ISSN~0278-0232. Available from: https://dx.doi.org/10.1002/hon.2798.

Detailed Information on Publication Record